Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADMP NASDAQ:CRVS NASDAQ:MTCR NASDAQ:NERV NASDAQ:SVRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMPAdamis Pharmaceuticals$1.28$0.75▼$26.18$7.26M1.27811,695 shs119,800 shsCRVSCorvus Pharmaceuticals$7.14-0.6%$6.30$2.54▼$10.00$532.00M0.57805,999 shs238,037 shsMTCRMetacrine$0.58$0.57$0.30▼$0.59$24.75M-0.73225,834 shs83,889 shsNERVMinerva Neurosciences$4.97-7.6%$2.43$1.15▼$12.46N/A-0.3937,981 shs613,304 shsSVRASavara$4.21+2.3%$3.48$1.89▼$4.42$726.79M0.461.29 million shs494,475 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for November 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMPAdamis Pharmaceuticals0.00%0.00%0.00%0.00%0.00%CRVSCorvus Pharmaceuticals-0.28%-6.63%+18.87%+51.16%-7.35%MTCRMetacrine0.00%0.00%0.00%0.00%0.00%NERVMinerva Neurosciences-16.07%+114.34%+158.65%+147.93%+116.94%SVRASavara-2.84%+14.17%+17.77%+61.18%+18.79%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMPAdamis Pharmaceuticals$1.28$0.75▼$26.18$7.26M1.27811,695 shs119,800 shsCRVSCorvus Pharmaceuticals$7.14-0.6%$6.30$2.54▼$10.00$532.00M0.57805,999 shs238,037 shsMTCRMetacrine$0.58$0.57$0.30▼$0.59$24.75M-0.73225,834 shs83,889 shsNERVMinerva Neurosciences$4.97-7.6%$2.43$1.15▼$12.46N/A-0.3937,981 shs613,304 shsSVRASavara$4.21+2.3%$3.48$1.89▼$4.42$726.79M0.461.29 million shs494,475 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for November 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMPAdamis Pharmaceuticals0.00%0.00%0.00%0.00%0.00%CRVSCorvus Pharmaceuticals-0.28%-6.63%+18.87%+51.16%-7.35%MTCRMetacrine0.00%0.00%0.00%0.00%0.00%NERVMinerva Neurosciences-16.07%+114.34%+158.65%+147.93%+116.94%SVRASavara-2.84%+14.17%+17.77%+61.18%+18.79%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMPAdamis Pharmaceuticals 0.00N/AN/AN/ACRVSCorvus Pharmaceuticals 2.60Moderate Buy$13.7592.71% UpsideMTCRMetacrine 0.00N/AN/AN/ANERVMinerva Neurosciences 1.50Reduce$5.000.60% UpsideSVRASavara 2.78Moderate Buy$7.8386.29% UpsideCurrent Analyst Ratings BreakdownLatest SVRA, NERV, ADMP, CRVS, and MTCR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/23/2025SVRASavaraCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform10/23/2025SVRASavaraJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$8.00 ➝ $11.0010/20/2025SVRASavaraWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$7.0010/14/2025SVRASavaraLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy10/13/2025CRVSCorvus PharmaceuticalsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$16.0010/13/2025CRVSCorvus PharmaceuticalsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$16.0010/8/2025CRVSCorvus PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025NERVMinerva NeurosciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)10/8/2025SVRASavaraWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025CRVSCorvus PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025NERVMinerva NeurosciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)(Data available from 10/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMPAdamis Pharmaceuticals$4.76M0.00N/AN/A($1.26) per share0.00CRVSCorvus PharmaceuticalsN/AN/AN/AN/A$0.51 per shareN/AMTCRMetacrineN/AN/AN/AN/A$1.36 per shareN/ANERVMinerva NeurosciencesN/AN/A$0.16 per share30.67($3.67) per shareN/ASVRASavaraN/AN/AN/AN/A$1.00 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMPAdamis Pharmaceuticals-$26.48MN/A0.00N/AN/A-502.73%-420.53%-256.87%N/ACRVSCorvus Pharmaceuticals-$62.29M-$1.01N/AN/AN/AN/A-28.61%-18.05%11/11/2025 (Estimated)MTCRMetacrine-$62.21M-$1.03N/A∞N/AN/A-84.88%-59.33%N/ANERVMinerva Neurosciences$1.44M$1.483.35N/AN/AN/A-41.35%31.37%11/4/2025 (Estimated)SVRASavara-$95.88M-$0.50N/AN/AN/AN/A-69.05%-54.84%11/11/2025 (Estimated)Latest SVRA, NERV, ADMP, CRVS, and MTCR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/11/2025Q3 2025CRVSCorvus Pharmaceuticals-$0.14N/AN/AN/AN/AN/A11/11/2025Q3 2025SVRASavara-$0.13N/AN/AN/AN/AN/A11/4/2025Q3 2025NERVMinerva Neurosciences-$0.35N/AN/AN/AN/AN/A8/14/2025Q2 2025NERVMinerva Neurosciences-$0.95-$0.43+$0.52-$0.43N/AN/A8/13/2025Q1 2025SVRASavara-$0.12-$0.14-$0.02-$0.14N/AN/A8/7/2025Q2 2025CRVSCorvus Pharmaceuticals-$0.13-$0.10+$0.03-$0.10N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADMPAdamis PharmaceuticalsN/AN/AN/AN/AN/ACRVSCorvus PharmaceuticalsN/AN/AN/AN/AN/AMTCRMetacrineN/AN/AN/AN/AN/ANERVMinerva NeurosciencesN/AN/AN/AN/AN/ASVRASavaraN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMPAdamis PharmaceuticalsN/A0.230.19CRVSCorvus PharmaceuticalsN/A8.918.91MTCRMetacrine0.3412.1512.15NERVMinerva NeurosciencesN/A6.156.15SVRASavara0.2511.0811.08Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMPAdamis Pharmaceuticals38.55%CRVSCorvus Pharmaceuticals46.64%MTCRMetacrine37.72%NERVMinerva Neurosciences34.56%SVRASavara87.93%Insider OwnershipCompanyInsider OwnershipADMPAdamis Pharmaceuticals1.30%CRVSCorvus Pharmaceuticals28.50%MTCRMetacrine13.80%NERVMinerva Neurosciences8.60%SVRASavara5.33%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADMPAdamis Pharmaceuticals119.36 million9.24 millionOptionableCRVSCorvus Pharmaceuticals3074.51 million53.28 millionOptionableMTCRMetacrine1042.57 million36.70 millionNot OptionableNERVMinerva Neurosciences9N/AN/ANot OptionableSVRASavara20172.84 million163.63 millionOptionableSVRA, NERV, ADMP, CRVS, and MTCR HeadlinesRecent News About These CompaniesINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara1 hour ago | prnewswire.comPomerantz Law Firm Announces the Filing of a Class Action Against Savara Inc. and Certain Officers - SVRA5 hours ago | prnewswire.comSavara price target raised to $11 from $8 at Citizens JMPOctober 23 at 8:49 AM | msn.comSavara Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before November 7, 2025 to Discuss Your Rights - SVRAOctober 23 at 8:45 AM | prnewswire.comJMP Securities Boosts Savara (NASDAQ:SVRA) Price Target to $11.00October 23 at 8:18 AM | marketbeat.comSavara Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SVRAOctober 23 at 5:50 AM | prnewswire.comSVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit with the Schall Law FirmOctober 23 at 4:28 AM | prnewswire.comSVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud LawsuitOctober 23 at 2:46 AM | prnewswire.comSavara Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm ...October 22 at 8:48 PM | caledonianrecord.comCSVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit with the Schall Law FirmOctober 22 at 4:44 PM | globenewswire.comROSEN, A LONGSTANDING LAW FIRM, Encourages Savara Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action– SVRAOctober 21 at 6:47 PM | globenewswire.comSavara Inc. (SVRA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud LawsuitOctober 21 at 5:09 PM | prnewswire.comShareholders that lost money on Savara Inc. (SVRA) should contact Levi & Korsinsky about pending Class Action - SVRAOctober 21 at 9:00 AM | prnewswire.comSavara (NASDAQ:SVRA) Trading Up 10.4% - Time to Buy?October 20 at 6:40 PM | marketbeat.comLevi & Korsinsky Reminds Savara Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 7, 2025 – SVRAOctober 20 at 4:20 PM | globenewswire.comDeadline Alert: Savara Inc. (SVRA) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud LawsuitOctober 20 at 1:03 PM | globenewswire.comPomerantz Law Firm Announces the Filing of a Class Action Against Savara Inc. and Certain Officers – SVRAOctober 20 at 12:01 PM | globenewswire.comClass Action Filed Against Savara Inc. (SVRA) Seeking Recovery for Investors - Contact The Gross Law FirmOctober 20 at 8:45 AM | prnewswire.comSavara (NASDAQ:SVRA) Earns Overweight Rating from Analysts at Wells Fargo & CompanyOctober 20 at 8:27 AM | marketbeat.comSVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit with the Schall Law FirmOctober 20 at 3:59 AM | prnewswire.comSavara Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SVRAOctober 20 at 3:39 AM | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSVRA, NERV, ADMP, CRVS, and MTCR Company DescriptionsAdamis Pharmaceuticals NASDAQ:ADMPAdamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company is headquartered in San Diego, California.Corvus Pharmaceuticals NASDAQ:CRVS$7.14 -0.05 (-0.63%) As of 02:34 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.Metacrine NASDAQ:MTCRMetacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.Minerva Neurosciences NASDAQ:NERV$4.97 -0.41 (-7.62%) As of 02:35 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.Savara NASDAQ:SVRA$4.20 +0.10 (+2.31%) As of 02:35 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Why Intuitive Surgical Is a No-Brainer for Long-Term Investors Is Oracle’s AI Rally Over? Wall Street Thinks ORCL Could Hit $400 3 Pharmaceutical Growth Stocks to Buy and Hold for 10 Years Why Micron Stock Could Soar 35% on AI Memory Demand WesBanco Insiders Signal Confidence With Coordinated Buys The Best AI for Picking Stocks, Ranked by Performance Will D-Wave's European Expansion Keep Fueling the Rally? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
